Therapy area located outside of head and neck;
Other skin diseases that might interfere with the efficacy evaluation;
Therapy area was previously received isotope or PDT or other treatment which might interfere with the efficacy evaluation;
Allergy to porphyrins and analogues; Photosensitivity; Porphyria; Allergic constitution;
Scar diathesis;
Immunocompromised conditions;
Electrocardiographic abnormalities or organic heart diseases;
Coagulation disorders;
Hepatic or renal functions abnormal (alanine aminotransferase or aspartate transaminase or total bilirubin > 1.5 upper limit of normal [ULN], or serum creatinine or blood urea nitrogen > 1.5 ULN);
Psychiatric diseases; Severe endocrinopathies;
Previous therapy of PWS within the last 4 weeks;
Participation in any clinical studies within the last 4 weeks;
Be judged not suitable to participate the study by the investigators
